Compositions and methods for preventing the proliferation and epithelial-mesenchymal transition of epithelial cells
Compositions and preparations of fetal support tissue that prevent or reduce the proliferation and epithelial-mesenchymal transition (EMT) of epithelial cells, wherein the epithelial cells may be human epithelial cells and the human epithelial cells may be conjunctival, retinal, corneal, limbal, or renal epithelial cells. Methods of preventing or reducing the proliferation, cell migration, and EMT of epithelial cells in an individual in need thereof, wherein the epithelial cells may be human epithelial cells and the human epithelial cells may be conjunctival, retinal, corneal, limbal, or renal epithelial cells. Methods of preventing or treating proliferative vitreoretinopathy in an individual in need thereof.
1. A method for preventing or reducing proliferation, cell migration, or epithelial-mesenchymal transition (EMT) of epithelial cells in an individual who has experienced retinal detachment, comprising: administering to the individual who has experienced retinal detachment a therapeutically effective amount of a composition, comprising:
(a) a preparation of fetal support tissue, wherein the preparation of fetal support tissue comprises heavy chain-hyaluronic acid/pentraxin 3 complex (HC-HA/PTX3); and
(b) a pharmaceutically acceptable diluent, excipient, vehicle, or carrier, thereby preventing or reducing the proliferation, cell migration, or EMT of epithelial cells.
2. The method according to claim 1 , wherein the fetal support tissue is placenta, placental amniotic membrane, umbilical cord, umbilical cord amniotic membrane, chorion, amnion-chorion, amniotic stroma, amniotic jelly, amniotic fluid, or a combination thereof.
3. The method of claim 1 , wherein the fetal support tissue is frozen or previously frozen.
4. The method according to claim 1 , wherein the epithelial cells are retinal pigment epithelial cells (RPE), conjunctival epithelial cells, corneal epithelial cells, limbal epithelial cells, retinal cells, or renal epithelial cells.
5. The method according to claim 1 , wherein the epithelial cells are human epithelial cells.
6. The method of claim 1 , wherein the preparation of fetal support tissue is an extract of fetal support tissue, micronized fetal support tissue, a homogenate, a powder, morselized fetal support tissue, pulverized fetal support tissue, ground fetal support tissue, purified heavy chain-hyaluronic acid/pentraxin 3 complex (HC-HA/PTX3), or a combination thereof.
7. The method according to claim 1 , wherein the composition is a gel, a solution, or a suspension.
8. The method according to claim 1 , wherein the composition is for local administration.
9. The method according to claim 1 , wherein the composition is formulated for intraocular injection, subretinal injection, intravitreal injection, periocular injection, subconjunctival injection, retrobulbar injection, intracameral injection or sub-Tenon's injection.